title: Effect of zinc-containing β-tricalcium phosphate nano particles injection on jawbone mineral density and mechanical strength of osteoporosis model rats.
abstract: Zinc-containing β-tricalcium phosphate (ZnTCP) nano particles were injected into zinc-deficient rats to promote osteogenesis. Sprague-Dawley (SD) rats (4 weeks old, average weight of 70 g) were divided into four groups: Normal rats (not ovariectomized (OVX)), Control rats (OVX), and OVX rats injected with a suspension of ZnTCP nano particles or ZnSO(4). The ZnTCP contained 6.17% zinc. The suspensions (0.6 mg as a zinc volume/0.2 ml) were injected around the jaw bone once a week for 12 weeks. Local effects on the bone mineral content (BMC) of jawbone, and systemic effects on body weight, the BMC of both femurs determined by X-ray computed tomography, and bone mechanical strength (BMS) measured by the three-point bending method, were examined. The BMC of jaw bone was significantly higher in the ZnTCP-treated group than un-treated or ZnSO(4)-treated group. Body weight, the BMC of femurs, and BMS were also significantly higher in the ZnTCP treated-group. The zinc-containing β-tricalcium phosphate nano particles were effective at preventing bone loss induced by ovariectomy in rats and have potential uses for treating periodontitis.
authors.affiliation: Institute of Pharmaceutical Sciences, Musashino University, Nishi-Tokyo, Tokyo 202–8585, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tokudome
authors.forename: Atsuo
authors.initials: A
authors.lastname: Ito
authors.forename: Makoto
authors.initials: M
authors.lastname: Otsuka
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001862:Bone Resorption / Q000517:prevention & control*; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003677:Deficiency Diseases / Q000150:complications / Q000188:drug therapy; D004195:Disease Models, Animal; D005260:Female; D005269:Femur / Q000187:drug effects; D007267:Injections; D007568:Jaw / Q000187:drug effects* / Q000378:metabolism; D053758:Nanoparticles; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D013314:Stress, Mechanical; D015032:Zinc / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate; D015032:Zinc